DISCREPANCY BETWEEN ONE STAGE CLOTTING AND CHROMOGENIC FACTOR VIII ACTIVITY IN WOMEN WITH HEMOPHILIA A AND HEMOPHILIA A CARRIERS: A retrospective clinical study.

J Thromb Haemost

Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France; Universite Claude Bernard Lyon 1, UR4609 Hemostase & Thrombose, Lyon, France. Electronic address:

Published: March 2025

Background: For every man diagnosed with hemophilia, approximately 1.6 women are expected to be carriers. Carriers are classified based on their Factor VIII (FVIII) levels and symptoms, ranging from asymptomatic to mild, moderate or severe symptoms. Close monitoring is critical for carriers with low FVIII levels or bleeding symptoms, as bleeding risk is difficult to assess due to inconsistent correlations with routine one-step assay (OSA) measurements.

Objective: This study hypothesized that the chromogenic FVIII assay (CSA) may provide valuable information for estimating bleeding risk in some hemophilia carriers.

Patients/methods: This retrospective study included 109 hemophilia A carriers from two centers.

Results: Among them, 23% had FVIII levels below 40 IU/dL using OSA, while 41% showed discrepancies when assessed using CSA. VWF activity and antigen levels were normal, with mean values of 84 IU/dL and 107 respectively. There was a significant correlation between OSA and CSA FVIII results, although 20 women had discordant results between the two methods. Bleeding events were reported in 49 women, including 18 surgical complications, 1 joint bleeding episode, and 30 cases of heavy menstrual bleeding, all occurring with normal VWF levels. There were 157 pregnancies in which 14 cases of postpartum hemorrhage were observed, 3 of which required transfusion or surgery.

Conclusion: This study highlights the significant discrepancies between OSA and CSA in FVIII results, with implications for diagnosis and bleeding risk assessment. It emphasizes the need to use both methods to identify women at higher risk of bleeding, especially before surgery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtha.2025.02.031DOI Listing

Publication Analysis

Top Keywords

fviii levels
12
bleeding risk
12
factor viii
8
hemophilia carriers
8
bleeding
8
osa csa
8
csa fviii
8
fviii
6
women
5
hemophilia
5

Similar Publications

DISCREPANCY BETWEEN ONE STAGE CLOTTING AND CHROMOGENIC FACTOR VIII ACTIVITY IN WOMEN WITH HEMOPHILIA A AND HEMOPHILIA A CARRIERS: A retrospective clinical study.

J Thromb Haemost

March 2025

Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France; Universite Claude Bernard Lyon 1, UR4609 Hemostase & Thrombose, Lyon, France. Electronic address:

Background: For every man diagnosed with hemophilia, approximately 1.6 women are expected to be carriers. Carriers are classified based on their Factor VIII (FVIII) levels and symptoms, ranging from asymptomatic to mild, moderate or severe symptoms.

View Article and Find Full Text PDF

Background: The development of inhibitory antibodies (inhibitors) is a serious complication in the treatment of hemophilia A with clotting factor VIII (FVIII) replacement therapy. Inhibitor formation critically depends on T cell help and modulation by regulatory T cells (Tregs).

Objective: In this study, we evaluated the F5111 immunocytokine (IC), a single chain fusion between the human interleukin-2 (IL-2) cytokine and an IL-2 antibody that biases cytokine activity towards cells with high IL-2 receptor alpha (IL-2Rα) expression, leading to extended IL-2 half-life and selective expansion of Tregs.

View Article and Find Full Text PDF

Background: Acquired haemophilia A (AHA) is a rare and severe bleeding disorder generally associated with pregnancy or aging. Spontaneous remission and prompt inhibitor eradication are described more frequently in postpartum cases. We evaluated retrospectively 15 postpartum AHA cases between 2007 and 2023 in order to evaluate response in terms of inhibitor eradication.

View Article and Find Full Text PDF

Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure.

View Article and Find Full Text PDF

Hemophilia A is a bleeding disorder caused by a deficiency in clotting factor VIII (FVIII), leading to recurrent joint bleeds, musculoskeletal damage, and chronic pain. The World Federation of Hemophilia (WFH) recommends prophylactic FVIII replacement therapy to reduce bleeding risk, yet joint deterioration and pain persist. Maintaining high FVIII levels provides clinical benefits but requires awareness of best practices and managed care considerations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!